Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
pancreatic neoplasms/povraćanje
Veza se sprema u međuspremnik
Page 1 od 28 rezultati
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
PRIMARY OBJECTIVES:
I. To evaluate and compare overall survival (OS) in patients with resectable pancreatic adenocarcinoma treated with perioperative fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin (modified [m]FOLFIRINOX) and surgery versus up-front surgery followed by
Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia,
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Patients with pancreatic cancer suffer from multiple symptoms related to the tumor itself or induced by the chemotherapy. The available supportive therapy is still not able to relief all symptoms that are caused by the malignancy itself as well as by the antineoplastic therapy.
Additionally,
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer continues to be a very lethal disease. It was estimated that in 2016, 53,070 Americans would be diagnosed with pancreatic ductal adenocarcinoma (PDA), and 41,780 would die from the disease. This makes pancreatic cancer the third leading cause of death from cancer in the US.
PDA is
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
The combination of Oxaliplatin and Gemcitabine has synergistic effects on a variety of human cancer cell lines in vitro. Clinically, it has demonstrated activity in other malignancies including lung, and pancreas. In the former study, poor prognosis advanced non-small cell lung cancer patients
Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Preoperative treatment can cause significant morbidity and often result in hospitalizations. Patients receiving preoperative FOLFIRINOX often experience numerous side effects, including nausea, vomiting, diarrhea, fatigue, fever, neuropathy, and loss of appetite. Frequently, patients require
FOLFIRINOX for 2nd-line Treatment of BTC
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer continues to be a very lethal disease. It was estimated that in 2016, 53,070 Americans would be diagnosed with pancreatic ductal adenocarcinoma (PDA), and 41,780 would die from the disease. This makes pancreatic cancer the third leading cause of death from cancer in the US.
PDA is
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic cancer continues to be a highly lethal disease with an overall 5 year survival of only 8%. Since 2004, the incidence of pancreatic cancer has been increasing by 1.5% per year and it is estimated that there will be 53,670 new cases diagnosed in the United States in 2017, with 43,090
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Surgical resection is the first choice treatment for patients with non-small-cell lung cancer. Although improvements of surgical techniques have reduced the incidence of complications, the long-term survival rate of postoperative patient is far from optimal. Cancer metastasis and recurrence are the
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer, in conjunction with Standard chemotherapy. OncoSil™, is an experimental treatment and carries the active treatment
High Energy High Protein Peptide Feed Study
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Malnutrition or "undernutrition" in adults (≥18 years of age) is the deficiency of nutrients (energy, protein and micronutrients) which causes adverse effects on bodily composition, clinical and functional outcomes. Malnutrition can occur as a result of a number of factors including inadequate
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Detailed description
The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer, in conjunction with Standard of Care (SOC) chemotherapy. OncoSil™, is an experimental treatment
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Study Groups:
If participant is found to be eligible to take part in this study, participant will be assigned to a combination dose level of the study drugs based on when participant joins this study. Up to 6 participants will be enrolled at each dose level. The first group of participants will
Najkompletnija baza ljekovitog bilja potpomognuta naukom
- Radi na 55 jezika
- Biljni lijekovi potpomognuti naukom
- Prepoznavanje biljaka po slici
- Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
- Pročitajte naučne publikacije povezane sa vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima
